$HCAT

Health Catalyst, Inc.

Health Catalyst provides data and analytics technology and services to healthcare organizations, primarily healthcare providers. Its clients include academic medical centers, integrated delivery networks, hospitals, physician practices, accountable care organizations, health information exchanges, health insurers and other risk-bearing entities. The company is headquartered in South Jordan, Utah. Its solution combines Ignite, a cloud-based healthcare data and analytics platform, software applications and professional expertise. Applications address clinical improvement, revenue and cost improvement, ambulatory operations, measures and registries, and data and analytics, including patient safety, revenue integrity, quality reporting, interoperability and cybersecurity. Services include data and analytics work, implementation, education, domain expertise and tech-enabled managed services. Health Catalyst serves most clients through subscription-based contracts, with additional services and technology offerings supporting clients’ data management and improvement work.

AlphAI earnings readThird quarter 2026 · NOV 5Health Catalyst Reports Third Quarter 2026 ResultsVerdict: weak

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $HCAT in the last 7 days.

—
$141K
Landry Benjamin
100%
See all $HCAT insider activity →

HCAT Q3 2026 deep dive: client retention and cost alignment take center stage

Health Catalyst (HCAT) reported Q3 2026 revenue of $56.28M, beating estimates by 1.5%, with adjusted EPS of -$0.03, also beating estimates. The company reconfirmed full-year revenue guidance of $247.5M and EBITDA guidance of $18.25M. CEO Simeon Kohl highlighted client retention as a priority, while the company is realigning costs and simplifying its product portfolio. HCAT is now debt-free with $79M in cash, aiming to improve margins and service delivery.

What Health Catalyst (HCAT) Said on Its Q3 Earnings Call

Health Catalyst (HCAT) reported Q3 revenue of $56.3M ($40.7M tech, $15.6M services), with adjusted gross margin falling to 44.3% from 52.6% YoY. Adjusted net loss was $0.03 per share. The company expects a Q4 adjusted EBITDA loss of $1.8M-$1.3M, citing Vitalware's removal and higher medical claims. HCAT ended Q3 with $79M in cash and no debt.

HCAT sentiment & insider activity

Recent HCAT coverage spans earnings, financial news and macro economy.

In the last 30 days, HCAT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($141K). The most active reporter was Landry Benjamin, General Counsel, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving HCAT

AlphAI scores every news story that mentions HCAT with an AI model for sentiment and relevance, and aggregates insider trades from Health Catalyst, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HCAT

Score

HCAT Q3 2026 deep dive: client retention and cost alignment take center stage

Health Catalyst (HCAT) reported Q3 2026 revenue of $56.28M, beating estimates by 1.5%, with adjusted EPS of -$0.03, also beating estimates. The company reconfirmed full-year revenue guidance of $247.5M and EBITDA guidance of $18.25M. CEO Simeon Kohl highlighted client retention as a priority, while the company is realigning costs and simplifying its product portfolio. HCAT is now debt-free with $79M in cash, aiming to improve margins and service delivery.

What Health Catalyst (HCAT) Said on Its Q3 Earnings Call

Health Catalyst (HCAT) reported Q3 revenue of $56.3M ($40.7M tech, $15.6M services), with adjusted gross margin falling to 44.3% from 52.6% YoY. Adjusted net loss was $0.03 per share. The company expects a Q4 adjusted EBITDA loss of $1.8M-$1.3M, citing Vitalware's removal and higher medical claims. HCAT ended Q3 with $79M in cash and no debt.

$HCATMedEarnings

Health Catalyst Reports Third Quarter 2026 Results

Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Health Catalyst Reports Third Quarter 2026 Results SALT LAKE CITY, UT, November 5, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported finan

$HCATLowExec change· appointed

Health Catalyst, Inc. (HCAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Health Catalyst Strengthens Its Board with the Appointment of Tami Reller Reller Joins Health Catalyst as it Enters Its Next Phase of Growth SALT LAKE CITY, Utah - September 14, 2026 - Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence

Health Catalyst Appoints Simeon Kohl As CEO And President

Health Catalyst appointed Simeon Kohl as CEO and President, effective September 14, 2026. Kohl succeeds Ben Albert, who transitions to Chief Business Officer. Kohl previously led Performant Healthcare's sale for $670 million. Health Catalyst cited Kohl's operational leadership and shareholder value creation. The company focuses on healthcare intelligence technology, with $2.8 billion in documented outcomes.

Related tickers